NCT05775705View on ClinicalTrials.gov

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

October 1, 2026

Conditions
PD-1 AntibodyHemophagocytic LymphohistiocytosisEpstein-Barr VirusLymphoma
Interventions
DRUG

L-DEP and PD-1 antibody

Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.

Trial Locations (1)

100050

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Friendship Hospital

OTHER

NCT05775705 - L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH | Biotech Hunter | Biotech Hunter